Healthcare - Biotechnology - NASDAQ - US
$ 6.17
-5.8 %
$ 524 M
Market Cap
-4.67
P/E
CASH FLOW STATEMENT
-67.4 M
OPERATING CASH FLOW
-38 M
INVESTING CASH FLOW
42 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Terns Pharmaceuticals, Inc.
| Net Income | -90.2 M |
| Depreciation & Amortization | 881 K |
| Capital Expenditures | -52 K |
| Stock-Based Compensation | 25.5 M |
| Change in Working Capital | 1.29 M |
| Others | -4.89 M |
| Free Cash Flow | -67.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (90.2) | (60.3) | (50.2) | (40.6) | (68.8) | (18.0) |
| Depreciation & Amortization | 0.9 | 1.0 | 0.5 | 0.4 | 0.2 | 65 K |
| Deferred Income Tax | 0.1 | 0.4 | 0.2 | 0.7 | 0.2 | 0.3 |
| Stock Based Compensation | 25.5 | 10.8 | 8.1 | 1.7 | 0.7 | 0.2 |
| Other Operating Activities | (5.0) | 81 K | 0.9 | 2.9 | (0.2) | (0.3) |
| Change in Working Capital | 1.3 | (1.0) | (1.4) | 5.1 | 1.8 | (0.4) |
| Cash From Operations | (67.4) | (49.1) | (41.8) | (29.8) | (66.2) | (18.1) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 52 K | (0.3) | (0.3) | (0.6) | (0.9) | (0.2) |
| Other Items | (37.9) | (22.0) | (119.4) | 7.3 | (3.0) | (4.5) |
| Cash From Investing Activities | (38.0) | (22.3) | (119.7) | 6.7 | (3.9) | (4.8) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 16.9 | 58 K | 58 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.3 | (0.2) | (2.0) | 68.6 | 4 K | 99.7 |
| Cash From Financing Activities | 42.0 | 167.5 | 134.4 | 85.5 | 62 K | 99.8 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (63.3) | 95.5 | (27.2) | 62.5 | (70.1) | 77.0 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (67.4) | (49.4) | (42.2) | (30.4) | (67.1) | (18.3) |